Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; hyprolose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zonisamide, quantity: 50 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; hydrogenated vegetable oil; sodium lauryl sulfate; titanium dioxide; purified water; gelatin; iron oxide black - zonisamide is indicated as:,- monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated;,- adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - zonisamide -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - zonisamide -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zonisamide, quantity: 100 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; colloidal anhydrous silica; microcrystalline cellulose; hydrogenated vegetable oil; titanium dioxide; sunset yellow fcf; purified water; allura red ac; gelatin - zonisamide is indicated as:,- monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated;,- adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - zonisamide -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zonisamide, quantity: 25 mg - capsule, hard - excipient ingredients: hydrogenated vegetable oil; sodium lauryl sulfate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified water; gelatin - zonisamide is indicated as:,- monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated;,- adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.

United States - English - NLM (National Library of Medicine)

directrx - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 50 mg - zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - zonisamide, quantity: 100 mg - capsule, hard - excipient ingredients: allura red ac; sodium lauryl sulfate; hydrogenated vegetable oil; titanium dioxide; microcrystalline cellulose; sunset yellow fcf; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - zonegran is indicated as: - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy who are intolerant to other agents or where other agents are contraindicated. - adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.